Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Why vaccines may fail in older adults: new study investigates immune cell role

NCT ID NCT06128915

Knowledge-focused Sponsor: State University of New York at Buffalo Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how a type of immune cell called neutrophils affects the body's response to the pneumococcal vaccine in young (21-40) and older (65+) adults. Researchers will measure how well neutrophils kill pneumonia bacteria after vaccination. The goal is to understand why vaccine responses decline with age, which could help improve vaccines for older populations.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Pneumococcal vaccine (20 serotypes)
What this could lead to
If successful, this could explain why older adults respond less to vaccines and point toward ways to improve vaccine effectiveness in the elderly.
What could go wrong
This is a small, early-stage observational study (60 participants) that measures immune cell activity, not clinical outcomes. It may not lead to any direct treatment or vaccine changes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2024

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Both sexes * Have not been vaccinated with any licensed or experimental pneumococcal vaccine * Ages 21-40; and ≥65. Individuals \>60 years old will also be recruited in case we find no unvaccinated people ≥65 years old * Free of acute infections within the last 2 weeks * Did not take any anti-inflammatory medicine in the last week * Did not ingest alcohol in the last 24 hours * Ability and willingness to provide consent Exclusion Criteria: * Previous vaccination with any licensed or experimental pneumococcal vaccine * Known hypersensitivity to vaccination and vaccine components * Immune deficiency * Use of immune-modulating or suppressive drugs * Malignancies within the last 2 years * Known hematological, rheumatic and inflammatory diseases * Known chronic infections * Poorly controlled chronic cardiovascular and metabolic conditions * Pregnancy * Dementia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University at Buffalo

    RECRUITING

    Buffalo, New York, 14203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.